In December 2021, Foundation Medicine, Inc. received FDA approval for its FoundationOneCDx. The FoundationOneCDx is a next-generation sequencing-based in-vitro diagnostic device. It is FDA approved therapeutic in melanoma for the present and future. It is enabled with the BRAF inhibitor monotherapies targeting the BRAFV600E mutations and BRAF/MEK inhibitor combination therapies targeting the BRAFV600E or V600K mutations. It is considered an important step toward enabling simplified decision-making for oncologists. Such innovations by cancer diagnostics companies are driving the skin cancer diagnostics market growth.
With the new features and technologies, vendors attract new customers and expand their footprints in emerging markets. This factor is driving the growth of the skin cancer diagnostics market at a significant CAGR.
The skin cancer diagnostics market is segmented into type and screening type. Based on type, the market is segmented into melanoma and non-melanoma. Based on screening type, the market is segmented into skin biopsy, dermatoscopy, lymph node biopsy, imaging tests, and blood tests. Based on country, the market is segmented into Germany, the UK, France, Spain, Italy, and the Rest of Europe.
SkylineDx BV; AMLo Biosciences Limited; DermLite LLC; bioMerieux SA; NeraCare GmbH, F. Hoffmann-La Roche Ltd.; and Michelson Diagnostics Ltd. are among the leading companies in the Europe skin cancer diagnostics market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 886.6 Million |
| Market Size by 2028 | US$ 1,375.9 Million |
| CAGR (2021 - 2028) | 6.5% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered |
Europe
|
| Market leaders and key company profiles |
|
The Europe Skin Cancer Diagnostics Market is valued at US$ 886.6 Million in 2021, it is projected to reach US$ 1,375.9 Million by 2028.
As per our report Europe Skin Cancer Diagnostics Market, the market size is valued at US$ 886.6 Million in 2021, projecting it to reach US$ 1,375.9 Million by 2028. This translates to a CAGR of approximately 6.5% during the forecast period.
The Europe Skin Cancer Diagnostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Skin Cancer Diagnostics Market report:
The Europe Skin Cancer Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Skin Cancer Diagnostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Skin Cancer Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Skin Cancer Diagnostics Market
